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 Development of transferrin-bearing vesicles encapsulating aspirin for 
cancer therapy 
 
Originally developed for the treatment of inflammatory disorders, the non-steroidal anti-
inflammatory drug aspirin was shown to have a preventive effect against cancer in the past 
decades. Most importantly, recent studies suggested that it might also provide a therapeutic 
benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors 
at a therapeutic concentration following intravenous administration, thus resulting in lack of 
efficacy on tumors. 
In this work, we demonstrated that aspirin could be formulated in transferrin-bearing 
vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative 
efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin 
was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold 
compared to that of drug solution. These results are promising and support the optimization of 
this delivery system to further improve its potential as a therapeutic tool in combination with other 
anti-cancer therapies.   
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Introduction 
The non-steroidal anti-inflammatory drug aspirin is arguably the most commonly used 
synthetic drug in human history. It was originally developed for the treatment of 
inflammatory disorders, but was shown to have a preventive effect against cancer in the 
past decades (Alfonso et al. 2014; Rothwell et al. 2011). Most importantly, recent studies 
suggested that aspirin might provide a therapeutic benefit in the treatment of cancer in 
vitro. Several anti-cancer mechanisms of aspirin were ascribed to inhibition of the 
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Epidermal growth factor receptor (EGFR), down-regulation of Nuclear factor-κ B (NF-
κB) activity and Protein kinase B (PKB/Akt) activation and modulation of B-cell 
lymphoma 2 (Bcl-2) family proteins in a wide range of cancer cells (Kutuk and Basaga 
2003; Park et al. 2010; Stark et al. 2007; Xiang et al. 2010). Even in the same cancer 
(such as colorectal cancer), aspirin exerts antineoplastic actions against cancer cells with 
and without cyclooxygenase-2 (COX-2) expression via different mechanisms (Ashktorab 
et al. 2005; Voutsadakis et al. 2010). The mechanisms whereby aspirin exhibits anti-
proliferative activity are therefore very diverse, not entirely elucidated and still the object 
of intense investigation.   
However, despite its antineoplastic potential, aspirin failed to specifically reach 
tumors after intravenous administration, thus resulting in a lack of efficacy on tumors and 
possible secondary effects on healthy tissues (increased risk of bleeding, particularly 
intracranial bleeding) (Rose et al. 2011). Furthermore, as a result of its rapid metabolism 
and elimination, aspirin has a short half-life in the whole blood of 22.2 ± 3.9 min (Costello 
and Green 1982), leading to plasma aspirin concentrations much lower than those 
necessary to exert effective anti-cancer activity. Given the potential anti-proliferative 
properties of aspirin, it is highly important to target the delivery of this drug specifically 
to its site of action, at a therapeutic dose. 
On the basis that iron is essential for tumor cell growth and can be effectively 
carried to tumors by using transferrin receptors overexpressed on cancer cells (Calzolari 
et al. 2007; Daniels et al. 2006), we propose to encapsulate aspirin in transferrin-bearing 
vesicles to overcome this limitation. The combination of active targeting, resulting from 
the conjugation of transferrin (Tf) ligands to the vesicles, with the passive accumulation 
of delivery systems in tumors due to enhanced permeability and retention (Maeda 1992), 
has been widely used in tumor-targeted strategies (Fu et al. 2009; Fu et al. 2011; Karim 
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et al. 2017; Lemarié et al. 2012; Qian et al. 2002). We have previously prepared Tf-
bearing Solulan-based unilamellar vesicles and tocopheryl-based multilamellar vesicles 
encapsulating the green tea compound epigallocatechin gallate and palm oil compound 
tocotrienol, which presented the same anti-cancer therapeutic potential and delivery 
issues as aspirin. We demonstrated that these targeted formulations significantly 
increased the cellular uptake of the drugs in comparison with control vesicles and drug 
solution for all the tested cancer cell lines. In addition, the intravenous administration of 
these Tf-bearing nanomedicines resulted in a rapid and sustained tumor regression over 
one month on mice bearing subcutaneous tumors, with disappearance of 40% of the tested 
A431 epidermoid carcinoma and B16-F10 melanoma for both drugs (Fu et al. 2009; Fu 
et al. 2011; Lemarié et al. 2012).  
Building on these highly promising vesicles, we now would like to develop a 
novel Tf-bearing nanomedicine ultimately able to specifically deliver aspirin to tumors 
after intravenous administration, thus leading to an improved anti-cancer therapeutic 
effect without secondary effects to normal tissues. To date, no formulation of aspirin 
encapsulated in a tumor-targeted delivery system has been reported. 
The objectives of this study were therefore 1) to develop and characterize novel 
transferrin-bearing vesicles encapsulating aspirin and 2) to evaluate their in vitro 
therapeutic efficacy on various cancer cell lines. 
 
Materials and Methods 
Cell lines and reagents 
Aspirin (Acetylsalicylic acid), human holo-transferrin (Tf), hydrogenated 
phosphatidylcholine (HPC), cholesterol and all other chemicals that are not specifically 
mentioned below were purchased from Sigma Aldrich (Poole, UK). 1,2-distearoyl-sn-
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glycero-3-phosphoethanolamine-N-(Carbonyl-methoxypolyethyleneglycol 2000, 
sodium salt (DSPE-PEG2000) came from NOF Corporation (Tokyo, Japan). Cholesterol-
PEG5000-maleimide was obtained from Nanocs (New York, NY). A431 human 
epidermoid carcinoma and T98G glioblastoma were purchased from the European 
Collection of Cell Cultures (Salisbury, UK), while Bioware® B16-F10-luc-G5 mouse 
melanoma that expresses the firefly luciferase was obtained from Caliper Life Sciences 
(Hopkinton, MA). Dulbecco's Modified Eagle Medium (DMEM) and Roswell Park 
Memorial Institute (RPMI)-1640 cell culture media, fetal bovine serum, L-glutamine and 
penicillin-streptomycin came from Invitrogen (Paisley, UK). 
 
Preparation and characterization of transferrin-bearing vesicles entrapping aspirin 
HPC (19.2 mg), DSPE-PEG2000 (6.4 mg), cholesterol (5.3 mg) and cholesterol-
PEG5000-maleimide (1.1 mg), at molar ratios of 60: 6: 34: 0.5, were shaken in 1.96 mL 
PBS (pH 7.4) at 60 °C for 1 hour. Aspirin solution (40 µL, 20 mg, measured from a stock 
solution of 500 mg/mL prepared in dimethylsulfoxide) was then added to the mixture, 
followed by probe sonication using Sonics Vibracell® VCX 500 (Sonics®, Newtown, CT) 
for 5 x 2 minutes.  
Transferrin was then thiolated to be able to react with the thiol-reactive maleimide 
group of cholesterol-PEG-maleimide (Figure 1). To do so, 10 mg of transferrin were 
dissolved in 1 mL of 50 mM sodium phosphate and 150 mM sodium chloride buffer (pH 
8) and were then shaken with 85 µL of 10-fold molar excess of 2-iminothiolane (Traut's 
reagent, 2 mg/mL in distilled water) at 25 °C for 1 hour. The thiolated transferrin was 
then isolated from unreacted Traut's reagent using Vivaspin® 4 centrifuge tubes with a 
molecular weight cut-off of 5 000 Daltons (Sartorius Ltd., Epsom, UK), after 
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centrifugation at 9 500 rpm (10 500 g) for 15 min at 20 oC (Hermle® Z323K centrifuge, 
Wehingen, Germany).  
The control vesicles were immediately conjugated with the thiolated Tf by incubation 
with continuous stirring at 25 °C for 2 hours. Free aspirin and/or free Tf were removed 
from both Tf-bearing and control vesicles using Vivaspin® 6 centrifuge tubes with a 
molecular weight cut-off of 100 000 Daltons (Sartorius Ltd., Epsom, UK) by 
centrifugation at 7 500 rpm (6 600 g) for 15 min at 20 °C. 
Vesicles were visualized by transmission electron microscopy (TEM), using a FEI 
Tecnai TF20 (ThermoFisher Scientific, Waltham, MA) with a Gatan 794 MultiScan® 
camera (Gatan, Pleasanton, CA), as previously described (Aldawsari et al. 2011). 
The entrapment of aspirin in the vesicles was quantified by spectrofluorimetry using an 
Agilent Varian Cary Eclipse® spectrofluorometer (Agilent Technologies, Santa Clara, 
CA), following disruption of the vesicles with isopropanol. Fluorescence intensity was 
measured at the aspirin excitation wavelength (λexc: 298 nm) and emission wavelength 
(λem: 406 nm), with linearity range of 0.125 to 1.5 μg/mL. 
The amount of transferrin conjugated to the vesicles was measured by Lowry assay (Fu 
et al. 2009). Briefly, 1 mL of sodium potassium tartrate solution (2% w/v in distilled 
water) and 1 mL of cupric sulphate solution (1% w/v in distilled water) were added 
dropwise (under continuous stirring to avoid precipitation) into 25 mL of sodium 
carbonate anhydrous solution (2% w/v in 0.1 M NaOH) to make up Solution A.  The 
bovine serum albumin (BSA) was prepared as a standard protein solution (concentration 
ranging from 0 to 500 µg/mL). One hundred microliters of Tf-bearing or control 
liposomes (diluted 1:20 in PBS) or BSA standard solution, was mixed with 1 mL of 
Solution A and incubated at 25 °C for 10 min. Subsequently, 100 µL of 1N Folin-
Ciocalteu’s phenol reagent was added to these samples (with immediate vortexing), 
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followed by incubation at 25 °C for 30 min (protected from light).  The absorbance of 
each sample was determined at a wavelength of 750 nm using an Agilent Varian Cary® 
50 UV-Vis Spectrophotometer (Agilent Technologies, Santa Clara, CA). Blank 
liposomes were used as the reference cell to set zero.  The experiment was done in 
quadruplicates.  The amount of Tf was calculated by correlating the absorbance of each 
sample with the standard curve of BSA. The results were expressed as percentage of Tf 
conjugated to nanoparticles compared to the initial amount of Tf added. 
Size and zeta potential of the vesicles were respectively determined by photon correlation 
spectroscopy and laser Doppler electrophoresis using a Zetasizer Nano-ZS® (Malvern 
Instruments, Malvern, UK). 
 
Drug release from the vesicles  
To confirm that aspirin could be released from the vesicles, the release profile of the 
drug was determined by dialysis at pH 5.5, 6.5 and 7.4, respectively mimicking the 
subcellular endosome, the tumor extracellular environment and the physiological pH in 
normal tissue and blood. Each vesicular formulation (100 µg/mL in phosphate buffer) 
was placed into a SnakeSkin® dialysis tube with a molecular weight cut-off of 3 500 
Daltons (ThermoFisher Scientific, Waltham, MA) and was dialyzed against 200 mL of 
phosphate buffer (pH 5.5, 6.5 and 7.4) at 37°C under stirring at 100 rpm.  At specific time 
points (15, 30, 45 minutes, then every hour for the first six hours (2, 3, 4, 5 and 6 h), then 
every 2 hours for the next 6 hours (8, 10 and 12 h), and every 24 hours for 3 days), 1 mL 
sample of the dialysate was withdrawn in quadruplicates and replaced with an equal 
volume of fresh media. The amount of aspirin in the samples was quantified by 
spectrofluorimetry and reported as a percentage cumulative release. 
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In vitro biological characterization  
Cell culture  
A431, T98G and B16-F10-luc-G5 cell lines overexpressing transferrin receptors were 
grown in either DMEM (for A431 and T98G cells) or RPMI-1640 medium (for B16-F10-
luc-G5 cells) supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine and 
0.5% (v/v) penicillin-streptomycin. Cells were cultured at 37oC in a humid atmosphere 
of 5% CO2. 
 
Cellular uptake of aspirin  
Quantitative analysis of cellular uptake was performed by spectrofluorimetry. 
Cells were seeded in 6-well plates at a density of 2 x 105 cells/well and grown for 72 
hours before being treated with aspirin (200 µg/well), either entrapped in transferrin-
bearing vesicles, control vesicles or in solution. After 24 hours’ treatment, the cells were 
washed three times with 2 mL cold phosphate buffer saline (PBS) before addition of 
trypsin (500 µL/well) and incubation for 10 min at 37 oC to detach the cells. Cells were 
then lysed with 10% Triton-X (500 µL/well) and incubated for another 24 hours at 37 oC. 
Cell lysates were then centrifuged at 10 000 rpm (9 300 g) for 15 min using an IEC 
Micromax® centrifuge (ThermoFisher Scientific, Waltham, MA). The amount of aspirin 
in the supernatant was quantified by spectrofluorimetry (λexc: 298 nm, λem: 406 nm), using 
a FlexStation 3® multi-mode microplate reader (Molecular Devices, Sunnyvale, CA). 
Untreated cells were used as blanks to remove any possible interferences of the cells and 
medium with the measurements.  
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In vitro anti-proliferative activity 
A431, T98G and B16-F10 cells were seeded at a density of 2 x 103 cells per well in 96-
well plates and grown for 72 hours before being treated with aspirin entrapped in 
transferrin-bearing vesicles, control vesicles, or in solution (final drug concentrations of 
100 to 500 µg aspirin/mL). Following 72 hours’ treatment, anti-proliferative activity of 
the formulations was evaluated by measurement of the growth inhibitory concentration 
for 50% of the cell population (IC50) in a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay (n=15). Briefly, 50 µl of MTT solution (0.5% 
w/v in PBS) was added to each well and incubated for 4 hours at 37 ºC, protected from 
light. The solution was then replaced with DMSO (200 µL per well) to solubilize the 
precipitated formazan product. The absorbance of the solution was measured at 570 nm 
using a Multiskan Ascent microplate reader (Thermo Labsystems, Beverly, MA). Dose-
response curves were fitted to percentage absorbance values to obtain IC50 values (three 
independent experiments with n=5 for each concentration level). 
 
Statistical Analysis 
Results were expressed as mean ± standard error of the mean (S.E.M).  Statistical 
significance was assessed by one-way analysis of variance (ANOVA) and Tukey multiple 
comparison post-test, using Minitab® 17.1.0 software (Minitab Ltd., State College, PE).  
Differences were considered statistically significant for P values lower than 0.05. 
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Results  
Preparation and characterization of transferrin-bearing vesicles entrapping aspirin 
Transferrin-bearing and control spherical unilamellar vesicles entrapping aspirin have 
been successfully prepared, as confirmed by TEM imaging (Figure 2). The percentage of 
drug loading within these vesicles was respectively 97.36 ± 0.02% (9.74 ± 0.01 mg/mL, 
54.04 ± 0.01 mM) for transferrin-bearing vesicles and 98.97 ± 0.01% (9.90 ± 0.01 mg/mL, 
54.94 ± 0.01 mM) for control vesicles. Holo-transferrin was conjugated to the vesicles at 
a level of 5.14 ± 0.11 mg (51.37 ± 1.06% of the initial transferrin added, 2.57 ± 0.06 mg 
Tf per mL liposomes, 32.70 ± 0.80 µM or 160.60 ± 3.40 µg Tf per mg of liposomes). As 
expected, the conjugation of transferrin to the surface of vesicles resulted in a larger mean 
vesicle size of 208.40 ± 3.86 nm (polydispersity: 0.36 ± 0.02) than that of control vesicles 
(106.60 ± 1.30 nm, polydispersity: 0.20 ± 0.01). These vesicle sizes were also confirmed 
by TEM imaging. Additionally, the conjugation of transferrin also increased their zeta 
potential compared to that observed for control vesicles (18.40 ± 0.46 mV and -15.50 ± 
0.95 mV respectively for transferrin-bearing and control vesicles). 
 
Drug release from the vesicles  
Transferrin-bearing and control vesicles exhibited an initial fast release of aspirin (about 
20 to 30 %) in the first hour, followed by a sustained release of the drug in a pH-dependent 
manner over 72 hours (Figure 3). In addition, the conjugation of a targeting ligand to the 
surface of the vesicles had an impact on the release profile of the drug. Specifically, at 
pH 7.4, 99.04 ± 0.41% of the drug was released from transferrin-bearing vesicles over a 
72-hour period, while 83.16 ± 0.25% and 61.56 ± 0.10% of the drug was released from 
these vesicles respectively at pH 6.5 and 5.5 during the same period. The drug release 
from the control vesicles followed a similar pH-dependent profile, but was slower than 
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for the targeted vesicles (cumulative drug release of 72.53 ± 0.37% at pH 7.4, 69.90 ± 
0.27% at pH 6.5, 59.96 ± 0.23% at pH 5.5 over 72 hours). 
 
Cellular uptake of aspirin 
The cellular uptake of aspirin following treatment with transferrin-bearing vesicles was 
significantly increased in comparison with control vesicles for the 3 cell lines, 
respectively by 1.2-fold in B16-F10 cells, 1.9-fold in A431 cells and 2-fold in T98G cells 
(Figure 4). Among these 3 cancer cell lines, the highest cellular uptake of aspirin was 
observed in B16-F10 cells, with 6.19 ± 0.42 µg, 4.87 ± 0.38 µg and 6.51 ± 0.38 µg aspirin 
in the cells following treatment with transferrin-bearing vesicles, control vesicles and the 
drug solution respectively. However, the cellular uptake following treatment with free 
aspirin was similar to that observed in Tf- bearing vesicles in all three cell lines, which 
might occur by passive diffusion. 
 
In vitro anti-proliferative activity  
The anti-proliferative efficacy of aspirin was significantly enhanced when formulated in 
vesicles, from 1.5- to 1.8-fold depending on the cell lines (Table 1, Figure 5). The 
conjugation of transferrin to the vesicles further improved this efficacy, by 2.1-fold for 
B16-F10 cells, 2.6-fold for A431 cells and at least 2.2-fold for T98G cells, compared to 
that of aspirin solution. The highest anti-proliferative efficacy was observed on B16-F10 
cells following treatment with aspirin loaded in transferrin-bearing vesicles (IC50: 197.97 
± 15.91 µg/mL). This result correlates well with the increased cellular accumulation of 
the drug encapsulated in the targeted vesicles, which was the highest for B16-F10 cells 
amongst the tested cell lines. The treatment of A431 and T98G cells by transferrin-
bearing vesicles encapsulating aspirin led to higher anti-proliferative efficacy compared 
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to control vesicles and free solution at most concentrations (with IC50 of 343.13 ± 19.24 
µg/mL and 227.22 ± 8.92 µg/mL respectively on A431 and T98G cells). The cell viability 
following treatment with the empty carriers was higher than 90% for the 3 cell lines.  
 
Discussion 
Aspirin has been reported to show a potentially preventive and therapeutic effect in many 
cancers. However, the possibility of using aspirin for cancer treatment is limited by the 
inability of the compound to specifically reach tumors at a therapeutic concentration once 
administration due to its short biological half-life, rapid metabolism and elimination. To 
overcome this issue, we hypothesize that loading aspirin into a tumor-targeted delivery 
system would enhance specific delivery of aspirin to cancer cells, resulting in an increase 
therapeutic efficacy and reduce secondary effects to healthy tissues. 
In this study, PEGylated liposomes were selected as carriers of aspirin as they 
demonstrated long blood circulation half- life achieved by sterically stabilized liposomes 
with PEG using DSPE-PEG2000 (Čeh et al. 1997). Liposomes also offer many 
advantageous properties as delivery systems, including biocompatibility, protection of 
the entrapped drugs from physiological environment and ability to carry large payloads 
of hydrophilic and hydrophobic drugs (Sercombe et al., 2015).  
Holo-transferrin has 10 to 100-times higher affinity for the transferrin receptor than that 
of iron-free transferrin at physiological pH (Richardson and Ponka 1997) and was 
therefore preferred as a transferrin receptor ligand in our study. We successfully prepared 
the vesicles entrapping aspirin with high drug loading. The high entrapment of the drug 
into the lipid bilayer of the liposomes was a direct result of the high lipophilicity of the 
drug (log P 1.19). Transferrin was conjugated to the vesicles using the thiol–maleimide 
‘click’ reaction, which showed similar conjugation level compared to our previous report 
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(around 50%) when using dimethylsuberimidate as a crosslinking (Dufès et al. 2000; 
Dufès et al. 2004).  
Transferrin-bearing vesicles entrapping aspirin displayed the required sizes for 
extravasation which has been found to be 400-600 nm for most tumors (Yuan et al. 1995), 
enabling them to be taken up by the transferrin receptor-expressing cancer cells. Zeta 
potential experiments demonstrated that transferrin-bearing vesicles entrapping aspirin 
were bearing a positive surface charge, unlike the negatively charged control vesicles.  
This zeta potential increase might be due to the release of ferric iron Fe3+ from transferrin 
at acidic pH. A study by Lamb and Leake (1994) demonstrated that transferrin (which is 
30% iron-saturated) released a negligible quantity of ferric iron at pHs 7.4 and 7.0.  
However, at acidic pH 5.5, around 4 µM ferric iron Fe3+ were released from Tf, which 
represents around 10% of the total iron bound to transferrin. As aspirin is an acidic 
compound, it facilitates the release of the positively charged ferric iron, thus resulting in 
an increase in zeta potential of Tf-bearing liposomes. This increased zeta potential 
(between 15 and 30 mV) is associated with higher stability of the vesicles (Das et al. 
2005). This combination of active targeting (based on the use of transferrin ligands) and 
passive targeting (based on the accumulation of delivery systems due to the enhanced 
permeability and retention) should provide tumor-selective targeting to the cancer cells.  
Drug release experiment indicated that aspirin could be efficiently released from its 
targeted vesicular formulation in a sustained manner, within 72 hours, which might 
further contribute to its therapeutic efficacy. Although a large percentage of the drug was 
released at pH 6.5 (mimicking the tumor extracellular environment) and 5.5 (mimicking 
the subcellular endosome), the highest percentage of drug release was obtained at pH 7.4, 
the physiological pH in normal tissue and blood. This formulation should therefore be 
further optimized to accomplish pH-triggered drug release only extracellularly in the 
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mildly acidic tumor tissues and intracellularly in the more acidic endosome following 
transferrin receptor-mediated endocytosis. The more pronounced drug release observed 
at pH 7.4 may be due to the intrinsic properties of the drug. The crossing of the lipid 
bilayer of the vesicles would occur when aspirin (pKa: 3.5) is in its conjugate base form. 
The ratios of aspirin conjugate base to protonated aspirin are respectively 7943, 1000 and 
100 at pH 7.4, 6.5 and 5.5. At a higher pH of 7.4, more aspirin is in the conjugate base 
form than at pH 6.5 and 5.5 and therefore available for crossing the lipid bilayer of the 
vesicles. The release of aspirin from transferrin-bearing vesicles was faster than from 
control vesicles. This might be explained by a possible membrane destabilizing effect of 
transferrin upon conjugation to liposomes, as described by Paszko and colleagues (2013) 
regarding another liposomal formulation. The release of aspirin from transferrin-bearing 
vesicles was similar to that previously described from solid lipid nanoparticles in 
combination with curcumin and sulforaphane (Sutaria et al. 2012). Albumin 
nanoparticles were also able to release the drug in a sustained and prolonged manner, 
with 90% of the drug released within 72 h (Das et al. 2005), similarly to our results. Other 
publications described a much faster release of aspirin than in our experiments. For 
example, 63% of aspirin was released from poly(4-vinylpyridine)-coated liposomes 
within 20 min at 37 °C, pH 7, followed by a slow, constant rate up to 140 min (Dong and 
Rogers 1993). In another study, 75% of aspirin was released from acacia-gelatin 
microencapsulated dipalmitoylphosphatidylcholine-based liposomes within 30 min, 
followed by a slow, constant release (Dong and Rogers 1993).  Thus, not pH-optimal yet, 
the controlled release observed in our experiments could have significant implications in 
future experiments, as it not only limits a “burst effect” of the drug, which occurs with a 
simple drug solution with a peak concentration after 30 min (Das et al. 2005), but also 
allows for a prolonged release of the drug. The rapid release of the drug observed within 
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1 h could be explained by the fact that positively charged liposomes display drug transfer 
rates faster than negatively charged liposomes, leading to the rapid release of drug 
payloads (Hefesha et al. 2011). The prolonged release of the drug observed within 72 h 
would result in a decrease of frequency of treatment injections, and maintenance of 
therapeutic coverage for prolonged duration. 
Cellular uptake studies demonstrated that the conjugation of transferrin to the vesicles 
significantly enhanced aspirin uptake in comparison with control vesicles on the three 
tested cell lines. These improvements were similar to that previously observed when 
using tocotrienol and epigallocatechin gallate as the carried drugs in transferrin-bearing 
Solulan-based vesicles (Fu et al. 2009; Lemarié et al. 2012). In addition, the highest 
uptake observed in B16-F10 cells might be a consequence of the fast growth rate of this 
cell line compared to the other tested cell lines. Liposomal uptake has been shown to be 
correlated with the growth of tumors, with fast-growing tumors having a higher drug 
uptake, although the causes of this correlation have not been elucidated yet (Bolkestein 
et al. 2016). The administration of aspirin as a solution resulted in a cellular uptake 
comparable to that observed with the transferrin-bearing vesicles. This might be 
explained by the fact that cellular uptake pathway of vesicles is different from that of free 
drug solutions: transferrin-bearing vesicles are specifically taken up by the cells 
overexpressing transferrin receptors via receptor-mediated (caveolae-mediated) 
endocytosis, control liposomes are mainly taken up by clathrin-mediated endocytosis, 
which is the main mechanism of nanomedicine internalization (Alshehri et al., 2018), 
while aspirin, which is a small molecule with a molecular weight of 188.18 Da, can be 
internalized by non-specific passive diffusion. We could not find any other studies 
reporting the cellular uptake of aspirin loaded in delivery systems to compare with our 
results.   
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In vitro treatment of the cells with transferrin-bearing vesicles and, to a lesser extent, 
control vesicles entrapping aspirin, resulted in an enhanced anti-proliferative activity on 
the three tested cell lines. Aspirin solution, however, only exerted a limited anti-
proliferative effect on these cells, even though the cellular uptake was similar to that of 
transferrin-bearing vesicles for these cell lines. This might be explained by the fact that 
vesicles bearing transferrin ligand and control vesicles facilitated the internalization of 
the drug respectively by caveolae-mediated endocytosis and by clathrin-mediated 
endocytosis. It is hypothesized that the uptake of the transferrin-bearing and control 
vesicles via endocytosis would result in a high accumulation of aspirin in the endosome, 
then in the cell nucleus, which would be essential for its anti-proliferative activity, unlike 
the dispersed diffusional accumulation observed with the free drug. Only one previous 
study with aspirin entrapped in a delivery system has reported anti-proliferative efficacy 
of this system (Zhou et al. 2015), but with experimental parameters that would not allow 
a comparison with our current results (co-delivery of aspirin with curcumin, 
encapsulation in PLGA nanoparticles, anti-cancer efficacy tested on ES-2 and SKOV3 
ovarian cancer cell lines).   
Aspirin has previously been encapsulated in various delivery systems, such as polymer-
silica composites (Kierys 2014), stearylamine-based liposomes (Kierys 2014), albumin 
nanoparticles (Das et al. 2005), acacia-gelatin microencapsulated 
dipalmitoylphosphatidylcholine-based liposomes (Dong and Rogers 1993) and poly(4-
vinylpyridine)-coated liposomes (Dong and Rogers 1992). It has also been co-
encapsulated in solid lipid nanoparticles with curcumin and sulforaphane (Sutaria et al. 
2012). However, to our knowledge, our present study describes for the first time a 
formulation of aspirin encapsulated in a tumor-targeted delivery system. The resulting 
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targeted delivery of the drug would allow a specific release of the drug to its site of action, 
in order to obtain an enhanced therapeutic effect against the cancer cells.  
This study demonstrated that aspirin has the ability to kill cancer cells in vitro, provided 
it is efficiently targeted to the cancer cells. However, the IC50 obtained with this targeted 
drug were still very low compared to the anti-cancer drugs commercially available, which 
limits its efficacy as a therapeutic molecule administered alone but encourages its use in 
combinatorial therapy. 
 
 
Conclusion 
We have demonstrated for the first time that aspirin could be formulated in tumor-
targeted vesicles and that this targeted formulation could lead to an increase in the anti-
proliferative efficacy of the drug in three cancer cell lines in vitro.  
Although the cellular uptake was similar for transferrin-bearing vesicles and the 
free drug solution, the in vitro therapeutic efficacy of aspirin was significantly improved 
when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug 
solution.  
These results are promising and support the optimization of this tumor-targeted 
formulation of aspirin to further improve its potential as a therapeutic tool in combination 
with other anti-cancer therapies.   
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Table with caption 
 
Table 1. Anti-proliferative efficacy of aspirin, either encapsulated in transferrin-bearing 
vesicles, control vesicles or free in solution, expressed as IC50 values, in B16-F10, A431 
and T98G cell lines (n=15). 
        
Cell lines IC50 (µg/mL) (mean ± S.E.M.) 
  
Tf-bearing 
vesicles 
Control 
vesicles 
Aspirin 
solution 
B16-F10 197.97 ± 15.91 244.46 ± 9.23 431.04 ± 10.91 
A431 343.13 ± 19.24 > 500 893.82 ± 60.84 
T98G 227.22 ± 8.92 332.24 ± 8.69 > 500 
 
 
 
  
25 
 
Figures 
Figure 1 
 
  
26 
 
Figure 2 
 
 
 
 
27 
 
Figure 3 
 
 
 
 
 
  
28 
 
Figure 4 
 
 
 
 
 
  
29 
 
Figure 5 
  
30 
 
Figure captions  
Figure 1. Conjugation of transferrin to the vesicles via thioether linkage 
 
Figure 2. Transmission electron micrograph images of transferrin-bearing (A) and 
control vesicles (B) entrapping aspirin (Bar: 500 nm).  
 
Figure 3. In vitro release of aspirin from transferrin-bearing (red) and control vesicles 
(blue) upon dialysis against PBS (pH 5.5 (■), 6.5 (●) and 7.4 (▲)) at 37oC for 72 h (n=4) 
(insert: in vitro release of aspirin from transferrin-bearing (red) and control vesicles for 
12h). 
 
Figure 4. Spectrofluorimetric quantification of the cellular uptake of aspirin (200 
µg/well), either encapsulated in transferrin-bearing vesicles (dark grey), control vesicles 
(light grey) or free in solution (white), in B16-F10, A431 and T98G cell lines (n=6) (*: 
p<0.05 vs transferrin-bearing vesicles treatment group). 
 
Figure 5. Anti-proliferative efficacy of aspirin, either encapsulated in transferrin-bearing 
vesicles (dark grey), control vesicles (light grey) or free in solution (white), in B16-F10 
(A), A431 (B) and T98G (C) cell lines (n=15) (*: p<0.05 vs transferrin-bearing vesicles 
treatment group). 
 
 
 
